Kaken Pharmaceutical Co., Ltd.
KKPCF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$984.57M
Close$
$29.75
14.4% upside
Current Fair Value
14.4% upsideUndervalued by 14.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $984.57 Million |
|---|---|
| Enterprise Value | $-52,512,734,566.00 |
| Annual dividend | $1.25 |
| Dividend yield | 4.95% |
| Earnings per Share | $57.52 |
| Beta | 0.13 |
| Outstanding Shares | 37,868,209 |
Return
| Return on Equity | 6.76% |
|---|---|
| Return on Assets | 5.52% |
| Return on Invested Capital | 6.79% |
Valuation & Multiples
| P/E Ratio | 14.1 |
|---|---|
| PEG | 0.47 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 1.04 |
| Enterprise Value to EBIT | 8.38 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$185.29 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.03
Consensus analyst estimateRevenue Estimate
$132.22 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Kaken Pharmaceutical Co., Ltd.
1,114 employees
CEO: Hiroyuki Horiuchi
Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensiv...